|

Palazestrant Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: OP-1250

Pipeline

Phase 1: 2Phase 3: 2

Top Sponsors

  • Olema Pharmaceuticals, Inc.4

Indications

  • Metastatic Breast Cancer4
  • Breast Cancer4
  • Cancer4
  • ER-positive Breast Cancer3
  • HER2-Negative Breast Carcinoma2

Gilbert, Arizona1 trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 1

Tucson, Arizona1 trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Denver, Colorado1 trial

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Sarasota, Florida1 trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.